Hexamethylene bisacetamide (Standard)

Hexamethylene bisacetamide (Standard) is the analytical standard of Hexamethylene bisacetamide. This product is intended for research and analytical applications. Hexamethylene bisacetamide (HMBA) is a differentiation inducer and selective bromine domain inhibitor that can differentiate across the blood-brain barrier. Hexamethylene bisacetamide can induce tumor cell differentiation and inhibit cell proliferation, showing antitumor activity. Hexamethylene bisacetamide induces apoptosis by Notch1, Bcl-2 and p53 signaling pathways. In addition, Hexamethylene bisacetamide improves the obesity phenotype of mice[1][2][3][4][5].

Product Specifications

CAS Number

[3073-59-4]

UNSPSC

12352100

Target

Akt; Apoptosis; Bcl-2 Family; Epigenetic Reader Domain; MDM-2/p53; NF-κB; Notch; p38 MAPK; Reference Standards

Related Pathways

Apoptosis; Epigenetics; MAPK/ERK Pathway; Neuronal Signaling; NF-κB; Others; PI3K/Akt/mTOR; Stem Cell/Wnt

Field of Research

Cancer; Metabolic Disease; Neurological Disease

Smiles

CC(NCCCCCCNC(C)=O)=O

Molecular Formula

C10H20N2O2

Molecular Weight

200.28

References & Citations

[1]Li XN, et al. Modulation effects of hexamethylene bisacetamide on growth and differentiation of cultured human malignant glioma cells. J Neurosurg. 1996 May;84 (5) :831-8.|[2]Dey A, et al. Hexamethylene bisacetamide (HMBA) simultaneously targets AKT and MAPK pathway and represses NF kappaB activity: implications for cancer therapy. Cell Cycle. 2008 Dec;7 (23) :3759-67.|[3]Cecchinato V, et al. Hexamethylene bisacetamide inhibits malignant phenotype in T-ALL cell lines. Leuk Res. 2008 May;32 (5) :791-7. https://pubmed.ncbi.nlm.nih.gov/17964649/ |[4]Nilsson LM, et al. Muralidharan SV, Demir D, Welin M, Bhadury J, Logan DT, Walse B, Nilsson JA. Cancer Differentiating Agent Hexamethylene Bisacetamide Inhibits BET Bromodomain Proteins. Cancer Res. 2016 Apr 15;76 (8) :2376-83.|[5]Park S, et al. HMBA ameliorates obesity by MYH9- and ACTG1-dependent regulation of hypothalamic neuropeptides. EMBO Mol Med. 2023 Dec 7;15 (12) :e18024.